Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 3
1957 1
1964 3
1966 2
1967 8
1981 1
1983 1
1985 1
1987 3
1988 5
1989 1
1991 3
1992 5
1993 2
1994 8
1995 5
1996 5
1997 3
1998 1
1999 3
2000 7
2001 2
2002 4
2003 8
2004 4
2005 9
2006 12
2007 9
2008 6
2009 3
2010 5
2011 7
2012 8
2013 10
2014 9
2015 7
2016 5
2017 6
2018 6
2019 11
2020 14
2021 17
2022 23
2023 18
2024 22
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

274 results

Results by year

Filters applied: . Clear all
Page 1
A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM; ICON7 Investigators. Perren TJ, et al. N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799. N Engl J Med. 2011. PMID: 22204725 Free article. Clinical Trial.
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Park-Simon TW, Rustin G, Joly F, Mirza MR, Plante M, Quinn M, Poveda A, Jayson GC, Stark D, Swart AM, Farrelly L, Kaplan R, Parmar MK, Perren TJ; ICON7 trial investigators. Oza AM, et al. Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23. Lancet Oncol. 2015. PMID: 26115797 Free PMC article. Clinical Trial.
Pasteurella Multocida.
Hasan J, Hug M. Hasan J, et al. 2023 May 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 May 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491561 Free Books & Documents.
VEGF antagonists.
Hasan J, Jayson GC. Hasan J, et al. Expert Opin Biol Ther. 2001 Jul;1(4):703-18. doi: 10.1517/14712598.1.4.703. Expert Opin Biol Ther. 2001. PMID: 11727506 Review.
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Banerjee S, et al. Among authors: hasan j. Ann Oncol. 2018 Apr 1;29(4):917-923. doi: 10.1093/annonc/mdy023. Ann Oncol. 2018. PMID: 29401246 Free article. Clinical Trial.
Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial.
Morgan RD, Clamp AR, White DJ, Price M, Burghel GJ, Ryder WDJ, Mahmood RD, Murphy AD, Hasan J, Mitchell CL, Salih Z, Wheeler C, Buckley E, Truelove J, King G, Ainaoui Y, Bhaskar SS, Shaw J, Evans DGR, Kilerci B, Pearce SP, Brady G, Dive C, O'Connor JPB, Wallace AJ, Rothwell DG, Edmondson RJ, Jayson GC. Morgan RD, et al. Among authors: hasan j. Clin Cancer Res. 2023 Jul 14;29(14):2602-2611. doi: 10.1158/1078-0432.CCR-22-3282. Clin Cancer Res. 2023. PMID: 36799931
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition gene.
Morgan RD, Burghel GJ, Flaum N, Schlecht H, Clamp AR, Hasan J, Mitchell C, Salih Z, Moon S, Hogg M, Lord R, Forde C, Lalloo F, Woodward ER, Crosbie EJ, Taylor SS, Jayson GC, Evans DGR. Morgan RD, et al. Among authors: hasan j. Genet Med. 2024 Oct;26(10):101230. doi: 10.1016/j.gim.2024.101230. Epub 2024 Jul 31. Genet Med. 2024. PMID: 39096152 Free article.
Trends in Bactericidal Nanostructured Surfaces: An Analytical Perspective.
Ishantha Senevirathne SWMA, Hasan J, Mathew A, Jaggessar A, Yarlagadda PKDV. Ishantha Senevirathne SWMA, et al. Among authors: hasan j. ACS Appl Bio Mater. 2021 Oct 18;4(10):7626-7642. doi: 10.1021/acsabm.1c00839. Epub 2021 Oct 4. ACS Appl Bio Mater. 2021. PMID: 35006714 Review.
274 results